

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 7, 2016**

**ADAPT IMMUNE THERAPEUTICS PLC**

(Exact name of registrant as specified in its charter)

**England and Wales**  
(State or other jurisdiction of  
incorporation)

**1-37368**  
(Commission File Number)

**Not Applicable**  
(IRS Employer Identification No.)

**101 Park Drive, Milton Park  
Abingdon, Oxfordshire OX14 4RY  
United Kingdom**  
(Address of principal executive offices, including zip code)

**(44) 1235 430000**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 

**Explanatory Note**

As previously announced, Adaptimmune Therapeutics plc (the "Company") has voluntarily decided to issue the reports required by the Securities Exchange Act of 1934, as amended (the "Exchange Act") on domestic company forms starting January 1, 2016. The Company has also changed its fiscal year from a June 30 to a December 31 fiscal year and as previously announced will file a Form 20-F transition report for the transition period from July 1, 2015 to December 31, 2015 by March 31, 2016 (the deadline required by the Exchange Act).

---

**Item 8.01. Other Events.**

On January 7, 2016, the Company issued a press release announcing that Professor P. Julian Dyson, Ph.D. has joined the Company as the head of the Autoimmune Group with responsibility for leading the expansion of the Company's T-cell therapy development activities to target certain autoimmune diseases.

A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein in its entirety.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. The following exhibit is filed as part of this Report on Form 8-K:

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated January 7, 2016.

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPT IMMUNE THERAPEUTICS PLC

Date: January 8, 2016

By: /s/ Margaret Henry  
Name: Margaret Henry  
Title: Corporate Secretary

3

---

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated January 7, 2016.

4

---



### Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications

PHILADELPHIA, Pa. and OXFORD, UK, January 7, 2016 — Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it is expanding its T-cell therapy development activities to target certain autoimmune diseases. Professor P. Julian Dyson, Ph.D. has joined the company as the head of the Autoimmune Group with responsibility for leading the autoimmune expansion, including the identification and validation of targets, and preclinical assessment of enhanced affinity TCRs directed against autoimmune targets.

“Professor Dyson is a luminary in the field of immune response regulation and, as such, is ideal to lead our expansion into autoimmune disease,” said James Noble, Chief Executive Officer. “He brings decades of research experience focused on the implication of T-cells in autoimmune diseases, and I would like to welcome him to the Adaptimmune team.”

Professor Julian Dyson joins Adaptimmune as Head of the new Autoimmune Group at the company’s research laboratories in Oxfordshire, U.K., with responsibility for leading the development of T-cell immunotherapy for autoimmune indications/conditions. Prof. Dyson brings 28 years of research experience in immunology working at the Medical Research Council and, since 2007, as Professor of Immunology at Imperial College London. The major focus of Prof. Dyson’s research has been on the regulation of immune responses. He has published over 100 papers including articles in Cell, Nature and PNAS. Among his professional activities, he has been a frequent invited lecturer at the Universities of Cambridge, Oxford, Cardiff, Southampton, London, Edinburgh, Milan, and Kyoto. Prof. Dyson received a BSc degree in Biochemistry from the University of Sussex and a Doctorate from the University of London.

Adaptimmune’s goal is to restore the function of the immune system and inhibit the autoimmune response by delivering affinity enhanced Regulatory T-cells, called Tregs, to the site of the disease. Tregs are a subpopulation of immune cells that are involved in maintenance of self-tolerance in healthy individuals and are thought to suppress the action of potential autoreactive lymphocytes that would otherwise recognize and destroy normal tissue, causing autoimmune diseases.

Adaptimmune believes that by delivering affinity enhanced antigen-specific Tregs to the site of an autoimmune disease, it can inhibit the autoimmune response and restore self-tolerance within the immune system, thus reducing the impact of the disease. The company believes that this approach may provide a better tolerated approach with fewer side effects than currently approved therapeutic options. Adaptimmune is currently validating a number of initial targets that are expressed in high amounts only on tissues involved in certain autoimmune diseases; these can then be used to develop specific affinity enhanced T-cell therapies.

#### About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery — the T-cell — to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: <http://www.adaptimmune.com>

#### Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission on October 13, 2015. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

#### Adaptimmune Contacts

Will Roberts  
Vice President, Investor Relations  
T: (215) 825-9306  
E: [will.roberts@adaptimmune.com](mailto:will.roberts@adaptimmune.com)

Margaret Henry  
Head of PR  
T: +44 (0)1235 430036  
Mob: +44 (0)7710 304249  
E: [margaret.henry@adaptimmune.com](mailto:margaret.henry@adaptimmune.com)